Tabid, Dan Aiza .
HRN: 20-46-76 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/10/2023
CEFTRIAXONE 1G (VIAL)
05/10/2023
05/17/2023
IV
1.2gm
Q24
PCAP-B
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes